Skip to content

Author

D. Buchsbaum

We have 4 of 27 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Editorial Open access Sep 2026

Editorial: Targeting the Wnt/β-catenin signaling pathway in cancer, volume II

Together, these studies emphasize that Wnt/ b -catenin signaling is controlled at multiple regulatory levels and cellular compartments, supporting context-speci c and biomarker-guided therapeutic strategies.

S. Patergnani, D. Buchsbaum, G. Piazza et al. · 0 citations
Jul 2026

Abstract B005: ADT-030, a novel PDE10 inhibitor that blocks RAS and β-catenin signaling with robust and durable antitumor activity and potential to mitigate resistance and on-target toxicities of monospecific RAS inhibitors

The results support IND-enabling studies of ADT-030 as a monotherapy or in combination with standard-of-care treatments for patients with a broad range of RAS-driven cancers, and especially for patients who relapsed after RAS inhibitor treatment.

Xi Chen, D. S. Bandi, G. Nagaraju et al. · 0 citations
Open access Aug 2026

HuB/HuR inhibition decreases HPV E6 and E7 proteins, stabilizes p53, and induces integrated stress to impair cervical cancer cell growth.

Findings indicate that, by decreasing RBPs, while inducing DNA damage and ISR, SRI-42127 reduces HPV oncoproteins, restores p53 function in HPV+ CaCxs, thereby enhancing their sensitivity to conventional chemotherapy.

Xi-Sheng Liu, S. Shrestha, Y. J. Edwards et al. · 0 citations
Jul 2026

Abstract A089: ADT-1004: A mechanistically distinct pan-RAS inhibitor with the potential to escape resistance and mitigate on-target toxicities that limit efficacy and safety of other RAS inhibitors

An orally bioavailable prodrug of ADT-1004, ADT-1004, demonstrated favorable tolerability and suppressed tumor growth in orthotopic and patient-derived xenograft models of pancreatic cancer, accompanied by reductions in activated RAS and p-ERK levels (Mol Cancer, 2025).

Junwei Wang, Xi Chen, Bandi D. S. Reddy et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.